Healthcare - Biotechnology - NASDAQ - US
$ 4.19
-2.1 %
$ 249 M
Market Cap
-3.3
P/E
CASH FLOW STATEMENT
-70.7 M
OPERATING CASH FLOW
-105 M
INVESTING CASH FLOW
5.93 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pyxis Oncology, Inc.
| Net Income | -73.8 M |
| Depreciation & Amortization | 1.93 M |
| Capital Expenditures | -6.73 M |
| Stock-Based Compensation | 16.9 M |
| Change in Working Capital | -11.7 M |
| Others | -12.3 M |
| Free Cash Flow | -77.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (73.8) | (120.7) | (76.0) | (12.8) | (2.8) |
| Depreciation & Amortization | 1.9 | 0.7 | 0.6 | 0.5 | 0 |
| Deferred Income Tax | 0 | 0 | 6.3 | 0 | 0 |
| Stock Based Compensation | 16.9 | 15.8 | 6.4 | 44 K | 28 K |
| Other Operating Activities | (4.1) | 10.4 | 20.6 | 56 K | (0.3) |
| Change in Working Capital | (11.7) | 4.5 | 6.7 | 2.3 | 0.5 |
| Cash From Operations | (70.7) | (89.3) | (35.3) | (10.1) | (2.2) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (6.7) | (6.4) | (0.5) | (1.5) | 0 |
| Other Items | (98.1) | 0 | 50 K | 0 | 0 |
| Cash From Investing Activities | (104.8) | (6.4) | (0.6) | (1.5) | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.2) | 0.2 | 151.7 | 32 K | 43.9 |
| Cash From Financing Activities | 5.9 | 0.2 | 304.0 | 35 K | 22.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (169.6) | (95.6) | 268.1 | (11.5) | 19.7 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (77.4) | (95.7) | (35.9) | (11.6) | (2.2) |